CY-101 + Pembrolizumab
Colorectal Cancer
Key Facts
About Cytovation
Cytovation ASA is a clinical-stage biotechnology company based in Norway that focuses on precision medicine for patients with β-catenin driven tumors. Built on over 15 years of research from the University of Bergen and Haukeland University Hospital, the company has developed CY-101, a stable synthetic peptide that selectively targets cancer cell membranes while inhibiting the β-catenin pathway. With multiple completed Phase I trials and upcoming Phase II studies, Cytovation aims to expand immunotherapy benefits to a broader range of cancer patients.
View full company profileAbout Cytovation
Cytovation ASA is a clinical-stage biotechnology company based in Norway that focuses on precision medicine for patients with β-catenin driven tumors. Built on over 15 years of research from the University of Bergen and Haukeland University Hospital, the company has developed CY-101, a stable synthetic peptide that selectively targets cancer cell membranes while inhibiting the β-catenin pathway. With multiple completed Phase I trials and upcoming Phase II studies, Cytovation aims to expand immunotherapy benefits to a broader range of cancer patients.
View full company profileTherapeutic Areas
Other Colorectal Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| M9140 | Merck KGaA | Phase 1/2 |
| Repositioned/Rerouted API | Reponex | Not Specified |
| Leronlimab | CytoDyn | Phase 2 |
| EGFR inhibitor | Acellera | Pre-clinical |
| Cannabics® RCC-33 | CNBX Pharmaceuticals | Preclinical |
| VCR-036 | Vicero Bio | Preclinical |
| CBI-1214 | Cartography Biosciences | Phase 1 |
| QL335 | QLSF Biotherapeutics | Phase 1 |
| Colorectal Cancer Detection Partnership | Daisy Genomics | Research/Assay Development |
| High Internalization ADC | Lytica Therapeutics | Preclinical |
| Undisclosed Colorectal Program(s) | Tavanta Therapeutics | Phase 2 |
| KRAS AK™PCR Mutation Screen Kit | Akcell Biotech | Commercial |